Exclusive Summary

• - Core patents expired in 2014–2015, opening most markets to generics, and the oral dissolving film (ODF) formulation offers differentiation across many countries.
• - Large unmet need across schizophrenia (~24M), bipolar disorder (~40M) and adjunctive MDD (~280M), with poor adherence common; ODF provides clear convenience and adherence benefits.
• - Widely recommended by major guidelines (APA, NICE, CANMAT) as a first-line or preferred atypical antipsychotic and first-line for bipolar mania, driving strong clinical acceptance.
• - Competition in tablets/ODT is mature, but ODF remains sparsely available, enabling first-to-market or differentiated positioning in multiple geographies.
• - US-FDA GMP and US registration de-risk quality/compliance and support rapid rollout, with substantial price advantage versus originator brands.